BECN1 Knockout DLD-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting the BECN1 gene in the DLD-1 colorectal adenocarcinoma cell line. This polyclonal format provides a heterogeneous loss-of-function model suitable for studying autophagy disruption in colorectal cancer biology.
The DLD-1 cell line is a human colorectal adenocarcinoma model with microsatellite instability-high (MSI-H) and mutations in APC, TP53, and KRAS. These genetic alterations drive tumorigenesis and influence dependency on autophagy, making DLD-1 a relevant system for investigating mechanisms of drug resistance and tumor survival.
Beclin-1, encoded by BECN1, nucleates autophagosome formation by scaffolding the class III PI3K/Vps34 complex with regulatory partners including ATG14, UVRAG, and AMBRA1. Its activity is governed by upstream kinases such as AMPK and mTOR via ULK1, and it directly interacts with Bcl-2, linking autophagy to apoptosis. Downstream effectors include ATG5, LC3, and p62, which execute autophagosome maturation and cargo degradation. The mTOR-ULK1-BECN1-Vps34-ATG14-ATG5-LC3-p62 axis is central to stress-responsive autophagy regulation.
In the context of DLD-1 cells with mutant KRAS and TP53, BECN1 knockout disrupts autophagic flux, potentially altering metabolic stress responses, proliferation, and chemosensitivity. This model enables dissection of autophagy-mediated survival pathways and provides a tool to assess the consequences of autophagy loss on tumorigenic potential and therapeutic resistance in colorectal cancer.
Researchers can utilize this knockout product for autophagic flux assays (LC3-II and p62 immunoblotting, LC3 immunofluorescence), cell viability and apoptosis measurements, and colony formation assays. Its application extends to xenograft tumor models and drug sensitivity profiling with oxaliplatin and 5-fluorouracil, facilitating the identification of autophagy-dependent vulnerabilities. For technical inquiries, contact Ascent Research.
